New nasal spray could ease public speaking panic for social anxiety sufferers
NCT ID NCT06358651
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 20 times
Summary
This study tests a nasal spray called fasedienol for quickly reducing anxiety during a public speaking challenge in adults aged 18 to 65 with social anxiety disorder. About 238 participants will receive either the spray or a placebo to see if it helps calm their distress. The goal is to provide a fast-acting, on-demand treatment for anxiety in stressful social situations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOCIAL ANXIETY DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vistagen Clinical Site
Phoenix, Arizona, 85012, United States
-
Vistagen Clinical Site
Fayetteville, Arkansas, 72703, United States
-
Vistagen Clinical Site
Little Rock, Arkansas, 72211, United States
-
Vistagen Clinical Site
Lafayette, California, 94549, United States
-
Vistagen Clinical Site
Oceanside, California, 92056, United States
-
Vistagen Clinical Site
Sherman Oaks, California, 91403, United States
-
Vistagen Clinical Site
Denver, Colorado, 80209, United States
-
Vistagen Clinical Site
Cromwell, Connecticut, 06416, United States
-
Vistagen Clinical Site
Jacksonville, Florida, 32256, United States
-
Vistagen Clinical Site
Lakeland, Florida, 33803, United States
-
Vistagen Clinical Site
Orlando, Florida, 32801, United States
-
Vistagen Clinical Site
West Palm Beach, Florida, 33407, United States
-
Vistagen Clinical Site
Chicago, Illinois, 60612, United States
-
Vistagen Clinical Site
Overland Park, Kansas, 66210, United States
-
Vistagen Clinical Site
Baltimore, Maryland, 21208, United States
-
Vistagen Clinical Site
Boston, Massachusetts, 02131, United States
-
Vistagen Clinical Site
Saint Charles, Missouri, 63304, United States
-
Vistagen Clinical Site
Las Vegas, Nevada, 89119, United States
-
Vistagen Clinical Site
New York, New York, 10128, United States
-
Vistagen Clinical Site
Media, Pennsylvania, 19063, United States
-
Vistagen Clinical Site
Memphis, Tennessee, 38119, United States
-
Vistagen Clinical Site
Fort Worth, Texas, 76104, United States
-
Vistagen Clinical Site
Draper, Utah, 84020, United States
-
Vistagen Clinical Site
Everett, Washington, 98201, United States
Conditions
Explore the condition pages connected to this study.